MedWatch

Major bank doubts Novo’s obesity-potential

One of the world’s largest banks has serious doubts about the commercial potential of Victoza following Novo Nordisk’s publication of obesity-studies with the drug. See why?

Foto: Colourbox

The price is too high and efficacy is not high enough compared with existing treatment options, says one of the world’s largest banks, Baclays, in an analysis memo about data from Novo Nordisk’s new obesity-studies with the diabetes drug, Victoza.

“It is the commercial opportunity for liraglutide in obesity over which we remain uncertain. Other, recently approved treatments appear to offer broadly similar efficacy in a similar population but are oral rather than injected and are much cheaper, at just $5-6/ day compared with $20-$25/ day. We see this as important in a market where reimbursement is tough,” the bank writes.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP anbefaler coronapille fra Pfizer

Pfizer har fået en positiv anbefaling fra CHMP, der anbefaler at tabletbehandlingen Paxlovid godkendes til behandling af covid-19. I Danmark er midlet dog allerede taget i brug.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier